JPMorgan analyst Lisa Gill does not expect major client pushback or earnings impact related to Express Scripts' (ESRX) termination of Linden Care from its pharmacy network. As such, she views today's pullback in shares of Express Scripts as a buying opportunity. The analyst notes that in its 2016 national preferred formulary, Express Scripts excluded two of Horizon Pharma's (HZNP) drugs, Duexis and Vimovo. The pharmacy benefits manager does dispense some of Horizon's orphan drug products through its Accredo Health specialty pharmacy, but the earnings contribution from these drugs is immaterial, Gill tells investors in a research note.